Systemic Review: Novel Approach for Solid Lipid Nanoparticles to Treat Pityriasis Versicolor

Solid lipid nanoparticles (SLNs) are a novel drug delivery system for the treatment of pityriasis versicolour, a skin infection of fungal origin from Malassezia species. SLNs encapsulate the antifungal agents therefore it increasing bioavailability, stability and reducing systemic side effects. Targeted drug delivery through the nanoscale carriers results in enhanced treatment efficacy and recurrence reduction. Antifungal agent-controlled and sustained release results in the increased clearance of the lesions and cure rates. SLNs provide deeper penetration into skin, circumventing the constraint of traditional topical preparations. Patient compliance is enhanced by reduced frequency of applications necessary for traditional treatments. SLNs can be customised with a range of antifungal compounds, making them an effective and versatile drug delivery system. Yet, stability concerns, drug expulsion, and regulatory approval must be overcome for clinical acceptance. Complex formulation approaches like polymer coating and surfactant optimisation can help improve SLN performance. Further studies should optimise nanoparticle size, drug loading efficiency, and long-term stability. Clinical trials are necessary to confirm the safety, efficacy, and commercial viability of SLN-based antifungal therapies. This review highlights the promise of SLNs in transforming dermatological treatments for fungal infections.